Opinion|Videos|July 24, 2024
Examining the Evolving 3L Treatment Landscape for mCRC
Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.
Advertisement
Episodes in this series
- Briefly Given the latest approvals, is there a continued role for regorafenib in mCRC and how do real-world outcomes support its use? (Yisilamu P, et al. ASCO 2024. Abstract e15562)
- Dr Marshall to Panel:Let’s explore sequencing strategies for CRC in the 3L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
- Dr Marshall to Panel: How would you describe your current approach to treatment sequencing?
- Dr Benson: How do you approach treating patients with fruquintinib from FRESCO and FRESCO-2 studies according to prior treatment sequence? (
Bekaii-Saab T, et al. ASCO 2024. Abstract 3579 .)- Impact of prior bevacizumab
- Dr Fakih:Please comment on recently presented data from the SUNLIGHT study and the implications on your treatment sequencing:
- Impact of prior fluoropyrimidine (
Fakih, et al. ASCO GI 2024. Abstract 114 ) - Impact of prior bevacizumab
- Impact of prior fluoropyrimidine (
- Dr Cohen: Regorafenib and/or TAS-102 sequencing (
Signorelli C, et al. ASCO 2024. Abstract e15553)
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.
Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
4
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
5